Ulcerative Colitis Cases Projected to Top 2 Million by 2031 Ulcerative Colitis Cases Projected to Top 2 Million by 2031
Diagnosed prevalent cases of ulcerative colitis in eight countries will top 2 million in 2031, with the United States having the most cases, according to newly released projections.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 16, 2023 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
AI Helps Predict Ulcerative Colitis Remission/Activity, Flare-ups AI Helps Predict Ulcerative Colitis Remission/Activity, Flare-ups
An AI tool can distinguish histological remission from activity in biopsies of UC and predict flare-ups -- and could have a role in both clinical trials and routine practice.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 14, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
AI Model Can Help Identify Ulcerative Colitis Remission, Activity
TUESDAY, March 14, 2023 -- An artificial intelligence (AI) model can distinguish histological remission from activity in biopsies of ulcerative colitis (UC) and can predict flare-ups, according to a study published online March 3 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 14, 2023 Category: Pharmaceuticals Source Type: news
Wake Forest Baptist patient ’s Post-it Note messages spread hope
Rebecca Barker is a 29-year-old patient who has been in and out of Atrium Health Wake Forest Baptist Medical Center for more than four years. She has ulcerative colitis, a condition affecting the digestive tract.
The disease has become very complicated, Barker said. “I’ve had close to 30 surgeries in the past 10 years.”
During Barker’s latest stay at Wake Forest Baptist, she started waving to patients and teammates she saw outside her window across the Comprehensive Cancer Center. She… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 14, 2023 Category: American Health Authors: Atrium Health Wake Forest Baptist Source Type: news
Nearly 1 in 3 Patients With IBD Affected by Skin Lesions Nearly 1 in 3 Patients With IBD Affected by Skin Lesions
No significant difference was found in skin lesion prevalence between patients with ulcerative colitis and Crohn ' s disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2023 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
IL-6 Inhibitor for UC Shows Some Promise in Mid-Stage Trial
(MedPage Today) -- Induction therapy with a novel interleukin 6 (IL-6) inhibitor for active ulcerative colitis yielded significantly higher rates of clinical response, remission, and mucosal healing than placebo, findings from a phase II study... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 7, 2023 Category: Gastroenterology Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
IBD: More Patients on Vedolizumab vs Anti-TNFs at 2 Years IBD: More Patients on Vedolizumab vs Anti-TNFs at 2 Years
Vedolizumab showed a higher overall 1- and 2-year persistence of use compared with two anti –tumor necrosis factor inhibitors in both Crohn ' s disease and ulcerative colitis.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 4, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
TREMFYA ® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
SPRING HOUSE, PENNSYLVANIA, March 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 inhibitors are the same by demonstrating a differentiated binding mechanism for TREMFYA® (guselkumab) from risankizumab. Findings show that guselkumab is able to dose-dependently bind to CD64+a myeloid cells,1 the predominant source of IL-23-driven inflammation in the gut.2,b Data comprise one of Janssen’s 22 oral and poster presentations at the 18th Congress of the European Crohn’s and Col...
Source: Johnson and Johnson - March 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
AGA Guideline Defines Role of Biomarkers in Ulcerative Colitis AGA Guideline Defines Role of Biomarkers in Ulcerative Colitis
In many cases, biomarkers should be considered before pursuing endoscopy or treatment adjustments.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 25, 2023 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Episode 1: PRIDE in Care: Inclusive Treatment for Patients With Ulcerative Colitis Episode 1: PRIDE in Care: Inclusive Treatment for Patients With Ulcerative Colitis
Drs Kane and Chedid discuss inclusive care for LGBTQIA+ patients, including sexual and gender minority terminology, asking about patients ' sexual preferences in clinic, and the health disparities faced by the LGBTQIA+ population with IBD.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2023 Category: Consumer Health News Tags: Gastroenterology InDiscussion Source Type: news
How to Best Treat Underserved IBD Patients
The incidence of inflammatory bowel disease (IBD) has risen significantly in recent decades, and some racial and ethnic minority groups have borne the brunt of that increase. Between 1970 and 2010, the incidence of IBD rose by 39% among white Americans. However, during that same period, the incidence of IBD among non-white Americans jumped by 134%. That’s according to a 2019 population-based cohort study in Therapeutic Advances in Gastroenterology.
There are multiple causes of ulcerative colitis and Crohn’s disease, the two primary medical conditions that comprise IBD. Genetic vulnerabilities, antibiotic overus...
Source: TIME: Health - February 15, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Gut health healthscienceclimate Source Type: news
Herbal Combination Tames Active Ulcerative Colitis: Study Herbal Combination Tames Active Ulcerative Colitis: Study
Derivatives of an intensely yellow spice and an intensely blue dye combined to resolve active ulcerative colitis in a small, randomized trial.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 3, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Genetic, Lifestyle Factors Independently Linked to IBD Risk
FRIDAY, Jan. 27, 2023 -- Genetic and lifestyle factors are independently associated with the risk for Crohn disease (CD) and ulcerative colitis (UC), according to a study published online Jan. 6 in The American Journal of Gastroenterology.
Yuhao... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 27, 2023 Category: Pharmaceuticals Source Type: news
Do Biologics Protect Against Cancer Progression in IBD? Do Biologics Protect Against Cancer Progression in IBD?
A Japanese study suggests that biologics and 5-aminosalicylic acid are potentially associated with a lower risk of advanced cancer in patients with ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 21, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
